title: Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption.
authors.forename: Yu
authors.initials: Y
authors.lastname: Sawada
authors.forename: Ryutaro
authors.initials: R
authors.lastname: Yoshiki
authors.forename: Chika
authors.initials: C
authors.lastname: Kawakami
authors.forename: Shoko
authors.initials: S
authors.lastname: Fukamachi
authors.forename: Kazunari
authors.initials: K
authors.lastname: Sugita
authors.forename: Motonobu
authors.initials: M
authors.lastname: Nakamura
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Tokura
mesh_terms: D000369:Aged, 80 and over; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives; D001706:Biopsy; D003131:Combined Modality Therapy; D003875:Drug Eruptions / Q000209:etiology* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000032:analysis*; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D019310:Pseudolymphoma / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D012867:Skin / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D013777:Tetrazoles / Q000009:adverse effects*; D016896:Treatment Outcome; D014467:Ultraviolet Therapy; D014633:Valine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000068756:Valsartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000893:Anti-Inflammatory Agents; D000959:Antihypertensive Agents; D017730:Ki-1 Antigen; D013777:Tetrazoles; D000068756:Valsartan; D001623:Betamethasone; D011239:Prednisolone; D014633:Valine